Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Cognitivism

Cognitivism

Cognitive psychology emerged as a significant field in the mid-20th century. It focused on understanding humans' internal mental processes. This approach emphasizes how people perceive, remember, think, and solve problems—elements critical to human cognition.
Previously dominated by behaviorism, which prioritized observable behaviors and largely ignored mental processes, psychology transformed in the 1950s. Cognitive psychologists argue that understanding how we think and process information is...

Cognitive Development During Adulthood

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...

Dementia

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.

Dementia l: Introduction

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Neuropsychological Functioning in Cognitively Normal, Older American Indians of the Southwestern United States.

Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists·2024

Same author

Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice.

Mayo Clinic proceedings·2024

Same author

Frontotemporal Dementia and the Sagging Brain.

Neurology·2022

Same author

Clinical Approach to Cognitive and Neurobehavioral Symptoms.

Continuum (Minneapolis, Minn.)·2021

Same author

When Is My Care Team Rounding? A Simple Signage Intervention to Increase Awareness of Rounding Times.

Journal of patient experience·2021

Same author

Quality improvement in neurology: Mild cognitive impairment quality measurement set.

Neurology·2019

Search research articles

Related Experiment Video

Updated: May 7, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Emerging biomarkers in cognition.

Meredith Wicklund¹, Ronald C Petersen

¹Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA.

Clinics in Geriatric Medicine

|October 8, 2013

Summary

This summary is machine-generated.

Early detection of dementia is advancing with biomarkers identifying synapse dysfunction and neurodegeneration. This review covers current biomarkers for Alzheimer disease-related mild cognitive impairment and emerging diagnostic tools.

Keywords:

Alzheimer disease Biomarkers Dementia

More Related Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Published on: February 14, 2014

Related Experiment Videos

Last Updated: May 7, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Published on: February 14, 2014

Area of Science:

Neurology
Neuroscience
Biomarker Research

Background:

Aging and dementia research is rapidly advancing.
Early identification of disease processes is crucial for intervention.
Biomarkers can detect pathological processes, synapse dysfunction, and neurodegeneration.

Purpose of the Study:

To review current biomarkers for mild cognitive impairment (MCI) due to Alzheimer disease (AD).
To discuss the utility and limitations of various imaging biomarkers.
To highlight emerging biomarkers for improved biological characterization.

Main Methods:

Review of structural magnetic resonance imaging (sMRI).
Analysis of fluorodeoxyglucose positron emission tomography (FDG-PET) and single-photon emission computed tomography (SPECT).
Evaluation of positron emission tomography (PET) with dopamine ligands.

Main Results:

Current biomarkers can identify early pathological processes in MCI due to AD.
Imaging techniques like sMRI, FDG-PET, and dopamine ligand PET show promise.
Existing biomarkers have notable limitations.
New biomarkers are continually emerging.

Conclusions:

Biomarkers are essential for early detection of Alzheimer disease-related mild cognitive impairment.
Continued development of novel biomarkers will enable more precise biological characterization of dementia.
Future research will likely lead to a broader spectrum of diagnostic tools.